Investors Hangout Stock Message Boards Logo
  • Mailbox
  • Favorites
  • Boards
    • The Hangout
    • NASDAQ
    • NYSE
    • OTC Markets
    • All Boards
  • Whats Hot!
    • Recent Activity
    • Most Viewed Boards
    • Most Viewed Posts
    • Most Posted
    • Most Followed
    • Top Boards
    • Newest Boards
    • Newest Members
  • Blog
    • Recent Blog Posts
    • Recently Updated
    • News
    • Stocks
    • Crypto
    • Investing
    • Business
    • Markets
    • Economy
    • Real Estate
    • Personal Finance
  • Market Movers
  • Interactive Charts
  • Login - Join Now FREE!
  1. Home ›
  2. Stock Message Boards ›
  3. Stock Boards ›
  4. Clene Inc. (CLNN) Message Board

New Test Identifies Parkinson’s Before Symptoms

Message Board Public Reply | Private Reply | Keep | Replies (0)                   Post New Msg
Edit Msg () | Previous | Next


Post# of 154
(Total Views: 108)
Posted On: 06/28/2024 4:52:15 PM
Avatar
Posted By: NetworkNewsWire
New Test Identifies Parkinson’s Before Symptoms Develop

Currently, more than 10 million individuals are affected by Parkinson’s disease around the world. This degenerative condition affects an individual’s nervous system and damages parts of the brain that control movement, causing involuntary shaking and stiff muscles as well as balance problems.

In addition to this, the disease also affects a patient’s mental health, causing anxiety and depression, insomnia and memory issues.

With the disease’s prevalence, there is an urgent need to develop better preventative strategies and treatments. This has proven difficult, particularly given researchers’ inability to identify individuals at risk of the illness while its in the early stages. By the time an individual is diagnosed with the disease, they have lost more than 60% of the cells that produce dopamine in the substantia nigra. This is the part of the brain that plays a significant role in modulating reward functions and motor movement.

Now, scientists have identified blood markers that may help show the presence of Parkinson’s disease up to seven years before symptoms begin presenting in patients.

Jenny Hällqvist, a biochemist from University College London, along with her colleagues utilized machine-learning models to find eight proteins in the blood that change as Parkinson’s progresses. The scientists began by comparing blood obtained from 99 patients who had recently been diagnosed with Parkinson’s, 26 individuals from the control group, and 72 patients who suffered from REM sleep behavior disorder.

Once this was done, they used a machine-learning model to narrow their findings to the most reliable blood markers. This allowed the scientists to forecast which individuals with REM sleep behavior disorders were more likely to develop Parkinson’s disease well before they began presenting with symptoms.

The biomarkers identified include proteins involved in cell development, biochemical pathways, blood clotting and inflammation. The scientists observed that some of them increased along with decreased cognitive performance and symptom severity.

Prior research has also demonstrated that a well-known protein observed in Parkinson’s patients, misfolded α-synuclein protein, stresses the endoplasmic reticulum. Two of the biomarkers, HSPA1L and HSPA5, also signal this organ to produce proteins when an individual is in a stressed condition.

In their conclusion, the scientists explained that the use of machine-learning models and these biomarkers allowed them to distinguish between early Parkinson’s disease from healthy controls.

If findings from this research can be replicated in bigger populations, a more effective blood test could be developed to identify individuals at risk. The scientists’ findings were reported in “Nature Communications.”

Hopefully, the early detection of Parkinson’s disease will increase the likelihood of therapeutics from companies such as Clene Inc. (NASDAQ: CLNN) delivering timely interventions to halt or even roll back this condition in its initial stages.

NOTE TO INVESTORS: The latest news and updates relating to Clene Inc. (NASDAQ: CLNN) are available in the company’s newsroom at https://ibn.fm/CLNN

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer



(0)
(0)




Clene Inc. (CLNN) Stock Research Links


  1.  
  2.  


  3.  
  4.  
  5.  






Investors Hangout

Home

Mailbox

Message Boards

Favorites

Whats Hot

Blog

Settings

Privacy Policy

Terms and Conditions

Disclaimer

Contact Us

Whats Hot

Recent Activity

Most Viewed Boards

Most Viewed Posts

Most Posted Boards

Most Followed

Top Boards

Newest Boards

Newest Members

Investors Hangout Message Boards

Welcome To Investors Hangout

Stock Message Boards

American Stock Exchange (AMEX)

NASDAQ Stock Exchange (NASDAQ)

New York Stock Exchange (NYSE)

Penny Stocks - (OTC)

User Boards

The Hangout

Private

Global Markets

Australian Securities Exchange (ASX)

Euronext Amsterdam (AMS)

Euronext Brussels (BRU)

Euronext Lisbon (LIS)

Euronext Paris (PAR)

Foreign Exchange (FOREX)

Hong Kong Stock Exchange (HKEX)

London Stock Exchange (LSE)

Milan Stock Exchange (MLSE)

New Zealand Exchange (NZX)

Singapore Stock Exchange (SGX)

Toronto Stock Exchange (TSX)

Contact Investors Hangout

Email Us

Follow Investors Hangout

Twitter

YouTube

Facebook

Market Data powered by QuoteMedia. Copyright © 2025. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges).
Analyst Ratings & Earnings by Zacks. RT=Real-Time, EOD=End of Day, PD=Previous Day. Terms of Use.

© 2025 Copyright Investors Hangout, LLC All Rights Reserved.

Privacy Policy |Do Not Sell My Information | Terms & Conditions | Disclaimer | Help | Contact Us